drugset / Trial / NCT00320307

Comparison of Abacavir Following Once-Daily And Twice-Daily Administration In HIV Infected Subjects

NCT00320307

Phase 1 Completed 30 enrolled GlaxoSmithKline
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of the study is to look at the levels of the drug abacavir (ABC) in blood. Also, the study will look at the levels of carbovir triphosphate (CBV-TP), which is the active substance produced from ABC in the bodyâ s cells which helps prevent HIV from multiplying. CBV-TP will be measured in specific blood cells. The amount of ABC and CBV-TP will be looked at when subjects receive ABC as a 300mg dose twice a day and compared with the levels when they receive ABC as a 600mg dose once a day.

Timeline

Start
2005-09
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Abacavir Other / unclassified 300 mg
Subject Abacavir Other / unclassified 600 mg